Objectives: To investigate the prevalence of fluoroquinolone resistance in Streptococcus pyogenes and its in vitro selection by ciprofloxacin and the respiratory fluoroquinolones, levofloxacin and moxifloxacin.
Introduction
The respiratory fluoroquinolones, levofloxacin and moxifloxacin, show good activity against respiratory tract pathogens resistant to the b-lactams or macrolides. Although fluoroquinolones are not yet recommended for respiratory infections due to Streptococcus pyogenes, they remain an attractive therapeutic option for penicillin-allergic patients especially in light of the high rates of macrolide-resistant S. pyogenes worldwide. 1, 2 However, resistance to the older fluoroquinolone analogues such as ciprofloxacin is becoming widespread in S. pyogenes. This is a result of point mutations, especially in the quinolone resistance determining regions (QRDRs) of genes encoding topoisomerase IV ( parC, parE) and DNA gyrase (gyrA, gyrB). 3, 4 Fluoroquinolone efflux by a reserpine-sensitive pump is also a common resistance mechanism to fluoroquinolones in Streptococcus pneumoniae, 5 although this mechanism still remains to be demonstrated for S. pyogenes.
We previously reported a clonal spread of fluoroquinolonenon-susceptible emm6 S. pyogenes in Belgium during 1999 -2002 carrying a Ser79Ala substitution in ParC. 4 The respiratory fluoroquinolones are active against these first-step parC mutants, though there have been concerns that their widespread use might select for second-step, high-level fluoroquinolone-resistant mutants. 6 Levofloxacin and moxifloxacin were introduced in Belgium in 1999 and 2002, respectively, and surveillance data from 2003 showed moxifloxacin consumption in Belgium to be one of the highest in Europe. 7 Recent studies have conclusively shown the link between antibiotic consumption and resistance emergence in respiratory pathogens. 8, 9 Hence, we studied the prevalence of fluoroquinolone resistance in S. pyogenes isolated from pharyngitis and invasive infections during 2003 -06, in Belgium. We also investigated the possible population evolution of fluoroquinolone-non-susceptible S. pyogenes by in vitro selection with ciprofloxacin and the respiratory fluoroquinolones, levofloxacin and moxifloxacin.
Materials and methods

Strain collection and identification
During 2003-06, 5851 S. pyogenes isolates were recovered from patients with tonsillopharyngitis, skin, wound or invasive infections from laboratories covering 10 Belgian provinces along with a standardized record of patients' ages, residential addresses and dates of isolation.
Susceptibility testing
All isolates were subjected to ciprofloxacin MIC testing by the agar dilution method, and those exhibiting ciprofloxacin MICs !2 mg/L were defined as fluoroquinolone-non-susceptible. 4, 10 To determine reserpine-sensitive efflux, all fluoroquinolone-non-susceptible isolates were screened for any change in ciprofloxacin MICs in the presence of 25 mg/L reserpine (Sigma Chemical Co., St Louis, MO, USA), an efflux pump-blocker. Isolates with ciprofloxacin MICs !4 mg/L were further screened for MICs of levofloxacin (Aventis, Romainville, France) and moxifloxacin (Bayer, Leverkusen, Germany) by agar dilution. Breakpoints used were those defined by the CLSI for S. pyogenes or S. pneumoniae (susceptible/resistant: in mg/L): levofloxacin, 2/!8 mg/L; and moxifloxacin, 1/!4 mg/L.
10
Genotypic studies
Clonality among the fluoroquinolone-non-susceptible isolates was investigated by PFGE using SmaI or SfiI (if refractory to SmaI restriction), as described previously.
11,12 Emm sequence typing was done according to the CDC protocol (http://www.cdc.gov/ncidod/ biotech/strep/strepindex.htm).
A total of 71 fluoroquinolone-non-susceptible isolates representing different clonal clusters/emm types were analysed for mutations in the QRDRs of parC, parE, gyrA and gyrB. Strains were selected proportionately based on the prevalence of the emm type and PFGE cluster, and within a cluster based on differences in MICs. Selected strains were sequenced on both strands on a 3730 DNA Analyser (Applied Biosystems, Foster City, CA, USA) utilizing BigDye Terminator (Version 3.1 Kit, Applied Biosystems) and published primers. 3 Nucleotide sequence alignment was done using SeqMan (DNASTAR Inc., Madison, WI, USA).
In vitro induction and selection
Fourteen fluoroquinolone-susceptible or -resistant clinical isolates of S. pyogenes were chosen for resistance selection studies with ciprofloxacin, levofloxacin and moxifloxacin. Of these, six strains were of the emm6 type, including one strain carrying a second-step gyrA mutation and showing high-level resistance to ciprofloxacin (MIC 32 mg/L) and five strains with first-step parC mutations and lowlevel ciprofloxacin resistance (MICs 2-8 mg/L). The other eight strains were chosen from four of the more prevalent fluoroquinoloneresistant emm types (emm1, emm12, emm28 and emm75) with one each of a fluoroquinolone-susceptible strain and a non-susceptible first-step mutant. This strategy also allowed a comparison of resistance selection within the same emm type. Tables 2 and 3 describe the clinical S. pyogenes emm types and the pre-selection MICs of ciprofloxacin, levofloxacin and moxifloxacin. The entire topoisomerase genes of these 14 strains were screened for mutations utilizing overlapping primers designed with the PRIMER3 software and detailed in Table S1 [available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)]. Three induction/selection cycles were carried out with each fluoroquinolone for each strain according to a previously described method with a few modifications. 13 Briefly, strains were grown overnight in antibiotic-free Todd-Hewitt broth supplemented with 2 g/L yeast extract (THY) at 378C in 5% CO 2 . Each strain suspension was inoculated into 2 mL of THY broth containing any of the three fluoroquinolones at 0.5-, 1-, 2-and 4-fold the MIC for the strain to obtain a density of %10 7 -10 8 cfu/mL (equivalent to a 0.5 McFarland standard). After overnight incubation at 378C in a shaker, cells growing in the broth with the highest fluoroquinolone concentration were inoculated on Trypticase soy agar II (BD, Erembogdem, Belgium) with 5% horse blood (blood agar) containing either of the three fluoroquinolones in serial doubling dilutions ranging from 0.06 to 512 mg/L. Plates were incubated at 378C in 5% CO 2 for 3 days and cultures that showed growth at a minimum of 2-fold the MIC for the parent or for the previous selection were purified on antibiotic-free plates and analysed for MICs, reserpine-sensitive efflux and further mutations in the entire parC and gyrA genes and QRDRs of parE and gyrB.
Frequency of mutation
We further estimated the mutation frequencies under moxifloxacin and levofloxacin selection pressure, of the double-mutant parent strain (A/emm6), its next-step mutant (A-1/emm6) and of a control emm6 strain with the characteristic Ser79Ala substitution in ParC (C/emm6) ( Table 2 ). Strains grown overnight in antibiotic-free THY broth to a density of %10 8 210 9 cfu/mL (equivalent to a 1 McFarland standard) were harvested by centrifugation, resuspended in brain heart infusion broth and spirally plated (Eddy Jet, The Netherlands) on blood agar plates with 2Â and 4Â MIC concentrations of moxifloxacin (range 1-32 mg/L) and levofloxacin (range 4 -64 mg/L) for the three strains, as well as on blood agar plates without antibiotics. After incubation at 378C with 5% CO 2 , colony counts were made at 24 and 72 h. Mutation frequencies were calculated from the ratio of the number of cfu on the antibioticcontaining plates to the number of cfu on the drug-free plates. If no colonies were observed on the antibiotic-containing plates for a particular multiple of the MIC, the frequency of mutation values for the corresponding drug was expressed as less than the number of cfu exposed, i.e. ,10 28 . Two to five randomly chosen mutant and parent colonies were studied for MICs of moxifloxacin or levofloxacin using Etest strips (AB Biodisk, Solna, Sweden). Experiments were performed in triplicate utilizing three separate overnight starter cultures for each strain.
Tests for statistical significance
Pearson's x 2 test was used to attribute statistical significance to differences in the yearly prevalence of fluoroquinolone-nonsusceptible S. pyogenes and to yearly changes in proportions of the emm6 type among fluoroquinolone-non-susceptible S. pyogenes. One-way ANOVA was performed to study differences in mutation frequencies between the emm6 strains A, A-1 and control, at 2Â and 4Â MIC of moxifloxacin or levofloxacin and after 24 and 72 h of incubation. P values of 0.05 (two-sided) were deemed significant.
Results
Emergence of high-level ciprofloxacin resistance and a secondstep gyrA mutation in a clinical emm6 S. pyogenes strain Four hundred and thirty-seven of the 5851 (7.47%) S. pyogenes isolates screened were identified to be fluoroquinolone-nonsusceptible during 2003-06 with the yearly distribution shown in Table 1 Table S2 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)]. Of the 5851 clinical S. pyogenes studied, the age of the patient sampled was known for 5498 isolates. Children and adults constituted 50.47% and 43.50% of the patients sampled, respectively. The proportion of fluoroquinolone-non-susceptible S. pyogenes recovered from paediatric patients increased from 30.77% in 2003 to 58.73% in 2005 and, despite the overall decrease in prevalence, remained 58.04% in 2006 (Table 1) .
We sequenced 71 fluoroquinolone-non-susceptible S. pyogenes isolates and all showed mutations in the QRDRs of the topoisomerase genes (Table S2) . Isolates with ciprofloxacin MICs 2-8 mg/L showed previously identified mutations in parC leading to predicted amino acid substitutions Ser79Ala (emm6) and Ser79Tyr or Ser79Phe (emm75). Three S. pyogenes also showed GyrA substitutions: (i) an emm81 strain (MICs of ciprofloxacin, levofloxacin and moxifloxacin of 2, 2 and 0.5 mg/L, respectively) showed a other QRDR/ non-QRDR CIP LVX MOX Ser79 (TCC) Asp83 (GAT) Asp91 (GAT) others single substitution, Asp102Gly in GyrA, without any substitutions in ParC/E or in GyrB; (ii) an emm2 strain (MICs of ciprofloxacin, levofloxacin and moxifloxacin of 4, 2 and 0.5 mg/L, respectively) showed a ParC and a GyrA substitution, Ser79Phe and Met99Leu, respectively; and (iii) an emm6 strain (MICs of ciprofloxacin, levofloxacin and moxifloxacin of 32, 8 and 1 mg/L, respectively) showed a Ser81Tyr substitution in GyrA along with the characteristic Ser79Ala substitution in ParC (Table S2) In vitro selection of high-level resistance to levofloxacin and moxifloxacin in the emm6 double-mutant strain
Fourteen fluoroquinolone-susceptible or -resistant clinical isolates of S. pyogenes were studied for resistance selection using various fluoroquinolones in three consecutive selection cycles. Tables 2 and 3 show the MICs of ciprofloxacin, levofloxacin and moxifloxacin for all the clinical parent and in vitro generated mutant strains analysed. In comparison with the other emm types studied, emm6 was most refractory to selection with fluoroquinolones. However, for the six emm6 strains tested, two strains (A and B) developed additional mutations and higher fluoroquinolone MICs (Table 2 ). For instance, the parent strain A/emm6 (carrying a second-step GyrA substitution) developed an additional ParC (Asp83Tyr) substitution under moxifloxacin selection. Compared with the parent strain, this in vitro mutant strain showed enhanced MICs of moxifloxacin (from 1 to 64 mg/L), levofloxacin (from 8 to 128 mg/L) and ciprofloxacin (from 32 to 64 mg/L). With levofloxacin, the selection of the parent A/emm6 strain resulted in a non-QRDR substitution in ParE (Val538Phe) with a 2-and 4-fold increase in levofloxacin and moxifloxacin MICs (16 and 4 mg/L, respectively), while the ciprofloxacin MIC remained at 32 mg/L. Ciprofloxacin selection did not result in any amino acid substitutions or increased MICs for strain A/emm6. For the parent strain B/emm6, a second-step GyrA substitution (Ser81Tyr) was observed with ciprofloxacin with 4-fold increased MICs of ciprofloxacin in comparison with the parent strain ( Table 2) . For the other emm types, all strains except one (strain J/emm12) developed additional mutations and higher MICs in the first induction/selection cycle irrespective of whether the parent was fluoroquinolone-susceptible or -resistant with firststep parC mutations ( Table 3) . Selection of the same clinical parent strain by the three fluoroquinolones generated different predicted substitutions at the known resistance hot spots at Ser79 in ParC and Ser81 in GyrA although the range of substitutions was limited. For instance, Ser79 in ParC was replaced either by a Phe, a Tyr or an Ala residue, and Ser81 in GyrA by Tyr or Phe. Of particular note, the Asp83Tyr substitution in ParC was only selected by the respiratory fluoroquinolones and in our strains consistently co-occurred with ParC Ser79Ala and GyrA Ser81Tyr substitutions. In the fluoroquinolone-susceptible strain K/emm28, moxifloxacin selected for a first-step mutation in parC (Ser79Ala) followed by second-step mutations in gyrA (Ser81Tyr) and in parC (Asp83Tyr). In strain N/emm75, ciprofloxacin selected for a tandem Ser79Phe79Tyr change, elevating ciprofloxacin MICs from 0.5 to 2 mg/L and to 4 mg/L. A few amino acid substitutions were also selected in ParE and GyrB although their contribution to fluoroquinolone resistance remains unclear. Results are from three experiments at each concentration for each strain. a Mean of three experiments for each strain at each MIC concentration. b P gives the probability calculated using one-way ANOVA. c Control strain (C/emm6, Table 2 ).
High mutation frequencies of the emm6 double-mutant strain under moxifloxacin pressure
Mutation frequencies under moxifloxacin and levofloxacin selection pressure were estimated for the double-mutant parent strain (A/emm6), its next-step mutant (A-1/emm6) and a control emm6 strain (C/emm6) at 2-and 4-fold MIC increases compared with the parent strain. Mean mutation frequencies under moxifloxacin selection at both 24 and 72 h for strain A were 500-to 30 000-fold higher than those for the control strain and 3000-to 30 000-fold higher than those for A-1 (P 0.05) ( Table 4 ). In contrast, differences in mutation frequencies between the three strains were minor under levofloxacin pressure. MICs for the selected mutants of the selecting antibiotic ranged from 4 to 16 and .32 mg/L for moxifloxacin and levofloxacin, respectively, for strain A, .32 mg/L for both moxifloxacin and levofloxacin for strain A-1, and 1 and 4 mg/L for moxifloxacin and levofloxacin, respectively, for the control emm6 strain.
Discussion
We report here an emergence of high-level ciprofloxacin resistance and a second-step gyrA mutation in a clinical strain of emm6 S. pyogenes recovered in Belgium from a throat swab of a 36-year-old female with tonsillopharyngitis. This emm6 double mutant also exhibited resistance to levofloxacin and reduced susceptibility to moxifloxacin. Although the MIC of moxifloxacin (1 mg/L) for the clinical emm6 double mutant was below the maximum serum concentration (3.6 mg/L) achieved with an oral dosage regimen of 400 mg daily, 14 the strain's in vitro evolution under moxifloxacin selection of high-level resistance to the respiratory fluoroquinolones was remarkable. In concordance, significantly higher mutation frequencies were observed for this emm6 strain in comparison with the control emm6 strain or its next-step mutant A-1 under moxifloxacin selection. These are highly unusual findings as, first, emm6 S. pyogenes are inherently refractory to mutation under fluoroquinolone selection pressure in vitro as observed in the present study and also shown previously, 13 and second, moxifloxacin is known to have one of the lowest selection potentials among the fluoroquinolones. 15 Also noteworthy were the low mutation frequencies of the in vitro mutant strain A-1 under moxifloxacin selection, comparable to those of the control emm6 strain. With an MIC of 8 mg/L, this strain was clinically resistant to moxifloxacin and the few mutants that emerged showed highlevel resistance to moxifloxacin with MICs .32 mg/L. Decreased mutation frequencies, in comparison with those of its progenitor strain A, might be indicative of a heavy biological cost to the organism upon acquisition of higher-level resistance to moxifloxacin and require further investigation.
We screened the entire topoisomerase genes of the clinical emm6 double mutant following selection with different fluoroquinolones, and detected among others, an additional ParC
